CD8A and COVID-19: In conclusion, the data show that by both AIM and ICS, CD8+ T cell responses to SARS-CoV-2 are less frequent and more difficult to detect in the early stages of acute COVID-19, and that no significant difference is detected in these responses as a function of disease severity.